Aims: PECAM-1 is an abundant endothelial cell surface receptor that becomes highly enriched at endothelial cell-cell junctions, where it functions to mediate leukocyte transendothelial migration, sense changes in shear and flow, and maintain the vascular permeability barrier. Homophilic interactions mediated by the PECAM-1 extracellular domain are known to be required for PECAM-1 to perform these functions; however, much less is understood about the role of its cytoplasmic domain in these processes. Main methods: CRISPR/Cas9 gene editing technology was employed to generate human endothelial cell lines that either lack PECAM-1 entirely, or express mutated PECAM-1 missing the majority of its cytoplasmic domain (ΔCD-PECAM-1). The endothelial barrier function was evaluated by Electric Cell-substrate Impedance Sensing, and molecular mobility was assessed by fluorescence recovery after photobleaching. Key findings: We found that ΔCD-PECAM-1 concentrates normally at endothelial cell junctions, but has the unexpected property of conferring increased baseline barrier resistance, as well as a more rapid rate of recovery of vascular integrity following thrombin-induced disruption of the endothelial barrier. Fluorescence recovery after photobleaching analysis revealed that ΔCD-PECAM-1 exhibits increased mobility within the plane of the plasma membrane, thus allowing it to redistribute more rapidly back to endothelial cell-cell borders to reform the vascular permeability barrier. Significance: The PECAM-1 cytoplasmic domain plays a novel role in regulating the rate and extent of vascular permeability following thrombotic or inflammatory challenge.
Introduction
Platelet endothelial cell adhesion molecule (PECAM-1, CD31) is a 130-kDa member of the immunoglobulin (Ig) superfamily that is expressed on the surface of hematopoietic progenitor cells, leukocytes, and platelets, and is highly enriched at the intercellular junctions of confluent endothelial cell monolayers [2, 37, 39] . PECAM-1 is comprised of a 118-residue cytoplasmic domain, a 19-residue transmembrane domain, and an extracellular domain containing six Ig homology domains, the amino terminal two of which mediate PECAM-1/PECAM-1 homophilic interactions [43, 51, 52] . Extracellular domain-mediated homophilic binding is critical for concentrating PECAM-1 at endothelial cell-cell junctions [50, 55] , where it plays an important role in maintaining endothelial barrier integrity following thrombotic or inflammatory challenge -a function that has been demonstrated both in vivo [9, 17, 21, 32, 33] and in vitro [30, 35, 45] .
The PECAM-1 cytoplasmic domain is encoded by eight exons [27] , is largely unstructured [42] , and carries out multiple functions in endothelial cells. Specifically, it is required for PECAM-1 to (1) function as part of a mechanosensory complex [11, 13, 26, 54] (2) confer cytoprotection in response to proapoptotic stimuli [4, 16, 19] , and (3) interact with other junctional adhesion proteins and cytoskeletal molecules [5] [6] [7] 22, 23, 54] . Studies of fusion proteins that contain the PECAM-1 extracellular Ig domains, but transmembrane and cytoplasmic domains of ICAM-1, have demonstrated that the PECAM-1 cytoplasmic domain is not required for its border localization [50, 55] . Little is known, however, about the influence of the PECAM-1 cytoplasmic domain on barrier integrity in endothelial cells.
We employed CRISPR/Cas9 gene editing technology to generate a series of novel human endothelial cell lines that either lack PECAM-1 entirely, or express a mutant form of PECAM-1 missing the majority of its cytoplasmic domain. These were then used to examine whether the PECAM-1 cytoplasmic domain regulates endothelial barrier function and, if so, how. Our results demonstrate that loss of the PECAM-1 cytoplasmic domain does not affect its ability to concentrate at the borders of confluent endothelial cells, but unexpectedly enhances its ability to maintain and restore endothelial junctional integrity after challenge. These results suggest that the ability of PECAM-1 to move freely within the plane of the plasma membrane is controlled by its cytoplasmic domain, which in turn determines the efficiency with which endothelial cells are able to establish and maintain their vascular permeability barrier.
Results

Creation of PECAM-1-deficient and PECAM-1 cytoplasmic domaindeleted human immortalized endothelial cell lines
Previous studies examining the function of the PECAM-1 cytoplasmic domain have been carried out using murine NIH3T3 cells [1, 15] , monkey Cos7 cells [1] , Chinese hamster ovary cells [55] , murine L-cells [1, 51] , murine brain endothelioma cells [54, 55] , bovine aortic endothelial cells [54] , and human mesothelioma cells [50] . Although these cell lines grow as adherent monolayers that allow PECAM-1, via diffusion trapping, to concentrate at cell-cell junctions, potential cytoplasmic and/or plasma membrane partners likely vary widely between each of these cell lines and authentic human endothelial cells. Because such components may provide an important context for the function of the PECAM-1 cytoplasmic domain, we used CRISPR/Cas9 technology to edit the PECAM-1 gene in human endothelial cells in situ to produce two novel immortalized cell lines: one in which PECAM-1 is missing completely (KO-PECAM-1 iHUVECs), and one in which only the PECAM-1 cytoplasmic domain has been deleted (Δ CD-PECAM-1 iHUVECs). A schematic diagram depicting sequences of the guide RNAs (gRNAs) used to create these cell lines, and the approximate location of their corresponding target sites in the PECAM-1 gene, is shown in Fig. 1 . KO-PECAM-1 iHUVECs were produced by transducing iHUVECs with a lentiviral vector encoding the Cas9 nuclease and gRNA 1 (Fig. 1B) to create an insertion/deletion mutation resulting in a premature stop codon within PECAM-1 exon 1. Δ CD-PECAM-1 iHUVECs were created using a lentiviral vector encoding Cas9 and gRNAs 10 ( Fig. 1C) and 16 (Fig. 1D) , resulting in deletion of the cytoplasmic domain bounded by exons 10 through 16. The cysteine residue that becomes palmitoylated [47] , as well as positively charged R and K residues that constitute the stop transfer sequence immediately inside the inner face of the plasma membrane, were intentionally left in place to prevent slippage of the transmembrane domain into and out of the lipid bilayer.
2.2.
Deletion of the PECAM-1 cytoplasmic domain does not affect the ability of PECAM-1 to localize at endothelial cell-cell borders Flow cytometry, employing monoclonal antibodies (mAbs) PECAM-1.3 and 235.1, which are specific for amino and C-termini of the PECAM-1, respectively (depicted in Fig. 1 ), was used to verify that KO-PECAM-1 iHUVECs lacked PECAM-1 expression, while the Δ CD-PECAM-1 iHUVECs expressed the extracellular, but not cytoplasmic, domain of PECAM-1. As expected, wild-type iHUVECs bound both mAbs ( Fig. 2A) , Δ CD-PECAM-1 bound only mAb PECAM-1.3 ( Fig. 2B) , while KO-PECAM-1 iHUVECs bound neither (Fig. 2C) . Confocal microscopy was then employed to assess the ability of wild-type PECAM-1 ( Fig. 2D-F ) and Δ CD-PECAM-1 ( Fig. 2G-I ) to become concentrated at endothelial cell-cell junctions. Reconstruction of the Z-axis in each of these micrographs demonstrates that Δ CD-PECAM-1 localizes to endothelial intercellular junctions to the same extent as does WT-PECAM-1, and both forms are largely absent from the apical surface in confluent endothelial cell monolayers. [30, 35, 45] , but little is known about the contribution of the PECAM-1 cytoplasmic domain to endothelial cell barrier function. Electric Cell-substrate Impedance Sensing (ECIS) technology, which can monitor subtle changes in endothelial cell barrier function in real-time [20] , was used to determine whether the PECAM-1 cytoplasmic domain plays a role in regulating vascular permeability. iHUVEC cell lines expressing WT-, Δ CD-, or KO-PECAM-1 were plated on gold electrodes to form confluent monolayers, and thrombin was used to disrupt junctional integrity. As shown in Fig. 3 , KO-PECAM-1 iHUVECs had poorer baseline barrier resistance, and exhibited a significantly slower rate of recovery of endothelial cell barrier function following thrombin challenge, than did endothelial cells expressing wild-type PECAM-1, as expected. In contrast, Δ CD-PECAM-1 iHUVECs exhibited tighter baseline resistance and a faster rate and extent of recovery of barrier restoration, suggesting that the cytoplasmic domain of PECAM-1 regulates its ability to contribute to the endothelial cell permeability barrier. 
Deletion of PECAM-1 cytoplasmic domain enhances the mobility of PECAM-1 within the plane of the endothelial cell plasma membrane
To account for the observation that cytoplasmic domain-deleted PECAM-1 forms tighter baseline barriers that are able to be restored more quickly following thrombotic or inflammatory challenge, we constructed lentiviruses encoding wild-type-and Δ CD-PECAM-1 fused to green fluorescent protein (GFP), and transduced them into PECAM-1-deficient iHUVECs. Flow cytometric and confocal microscopic analysis confirmed that both constructs were expressed to a similar degree on the cell surface (Fig. 4) , and capable of concentrating at cell-cell borders (Fig. 4 inset) . To examine the possibility that the cytoplasmic domain restricted the mobility of PECAM-1 within the plane of the endothelial cell plasma membrane, we subjected confluent monolayers of these cells to fluorescence recovery after photobleaching (FRAP) analysis. A high intensity laser was used to photobleach cell-cell junctional regions with similar intensities of PECAM-1 staining, after which the rate of recovery of fluorescence, which reports the migration of GFP-tagged molecules into the photobleached region, was quantified using confocal microscopy. As shown in Fig. 5 , GFP-ΔCD-PECAM-1 had a higher rate of diffusion within the plasma membrane compared to GFP-WT-PECAM-1.
Discussion
PECAM-1 is a cell adhesion and signaling receptor expressed on the surface of platelets and leukocytes, and is also the most abundant cell surface molecule on endothelial cells. PECAM-1 becomes highly concentrated at endothelial cell junctions via diffusion trapping -a passive process in which PECAM-1 molecules, diffusing laterally within the lipid bilayer of the plasma membrane, come into contact with PECAM-1 . of the slope from the nadir immediately after thrombin challenge to a point near full recovery. Statistics were carried out using one-way ANOVA analysis. *P < 0.05; **P < 0.01; ***P < 0.001. Note the increased baseline barrier resistance as well as the enhanced rate of barrier recovery following thrombin stimulation of iHUVECs expressing ΔCD-PECAM-1.
molecules on adjacent cells, interact homophilically in trans, and become "trapped" at the cell junction, where they embellish the permeability barrier [50] . While the presence of PECAM-1 at endothelial cellcell borders has been known to contribute to junctional integrity for > 20 years [17] , and that its absence results in increased vascular permeability under conditions of inflammatory, mechanical, or thrombotic stress [9, 21, 32, 33 ], the precise mechanism by which PECAM-1 contributes to junctional integrity, both under steady-state conditions and following barrier disruption, is incompletely understood.
Recent studies examining the barrier properties of endothelial cells, and other validated model cell systems that express mutant forms of PECAM-1 have begun to shed light on the molecular requirements for PECAM-1 to contribute to endothelial cell junctional integrity. Privratsky et al. knocked down expression of PECAM-1 in three different endothelial cell lines using siRNAs, and found, using ECIS technology, that loss of PECAM-1 resulted in both markedly reduced baseline barrier resistance, as well as a significantly decreased capacity to re-establish the endothelial cell permeability barrier following thrombin challenge [45] . Cells expressing a mutant form of PECAM-1 containing a single K89A mutation in Ig domain 1 known to abolish homophilic binding [40] exhibited poor barrier resistance properties, similar to those of cells expressing no PECAM-1 at all, demonstrating the importance of PECAM-1-mediated homophilic binding to junctional integrity. Lertkiatmongkol et al. have recently shown that a sialic acidcontaining glycan emanating from N25 reinforces dynamic endothelial cell-cell interactions by stabilizing the PECAM-1 homophilic binding interface [30] .
The importance of the PECAM-1 cytoplasmic domain in PECAM-1-mediated barrier functions has been less well studied. Cells expressing a mutant form of PECAM-1 in which functionally important immunoreceptor tyrosine-based inhibitory motif (ITIM) tyrosine residues had been mutated to phenylalanine exhibited normal baseline barrier resistance and restored vascular barrier integrity at a rate indistinguishable from cell expressing wild-type PECAM-1 [45] , demonstrating that ITIM-mediated cellular signaling downstream of PECAM-1-mediated homophilic binding plays no discernable role in supporting the endothelial cell permeability barrier. Whether other structural or Fig. 4 . Generation of iHUVEC cell lines expressing fulllength and ΔCD forms of human PECAM-1 fused to GFP. Lentiviral constructs encoding fusion proteins comprised of full-length wild-type PECAM-1 fused to GFP, or ΔCD-PECAM-1 fused to GFP, were transduced into CRISPRgenerated PECAM-1-negative iHUVEC cells. Transduced cells expressing similar levels of PECAM-1 were selected by fluorescence-activated cell sorting, and expression additionally evaluated by confocal microscopy (insets). The diffusion coefficients for wild-type and ΔCD-PECAM-1 were calculated from the FRAP images using ImageJ. Data are expressed as the mean ± the standard deviation of seven independent experiments. Significant differences are indicated as **P < 0.01. Scale bar = 20 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) functional features of the cytoplasmic domain might play a role in PECAM-1-mediated contributions to barrier function, however, were not examined.
In the present investigation, we employed CRISPR/Cas9 gene editing technology to remove exons 10-16 of the PECAM-1 gene in human endothelial cells (Fig. 1 ) so that we could examine the effects of deleting the cytoplasmic domain on both baseline and dynamic cell permeability barrier function. Editing the PECAM-1 gene in situ has the advantage of not affecting gene expression levels ( Fig. 2A-C) , while retaining the cellular and molecular regulatory context in which PECAM-1 is normally expressed. Consistent with previous studies employing cell lines transfected with cDNAs encoding PECAM-1 isoforms either lacking the cytoplasmic domain [15] or containing an irrelevant cytoplasmic domain [50, 55] , absence of the PECAM-1 cytoplasmic domain had no effect on the ability of PECAM-1 to, with time, localize to cell-cell borders (Figs. 2D-I and 4 insets) . When the kinetics of PECAM-1 receptor mobility were quantitatively examined using FRAP analysis of GFP-tagged forms of PECAM-1 with or without a cytoplasmic tail, however, we found that PECAM-1 receptors missing their cytoplasmic domain diffused more rapidly within the plane of the plasma membrane (Fig. 5) -a property that manifests itself functionally by conferring both improved baseline barrier resistance and a faster rate of re-establishing a permeability barrier following its disruption by thrombin (Fig. 3) . Taken together, these data suggest that the PECAM-1 cytoplasmic domain, perhaps via ITIM-independent interactions with one or more as yet unidentified cytosolic binding partners, functions as a previously unrecognized point of regulation by restraining PECAM-1 receptor mobility within the plane of the plasma membrane and the subsequent homophilic interactions that are important for forming the endothelial cell permeability barrier.
Cytoplasmic domains have been shown to regulate the function and subcellular location of many cell adhesion molecules, including vascular endothelial cadherin [28] , integrins [10, 34, 41] , selectins [25] , CD44 [31] , as well as other Ig superfamily CAMs [8, 44, 48] , often via their association with one or more elements of the actin or membrane cytoskeleton. The removal of the β-catenin-binding domain within the cytoplasmic tail of VE-cadherin has been reported to result in disorganization of adherens junctions and hyperpermeability of vascular endothelial cells [36] . Similarly, calpain-mediated cleavage of N-cadherin showed reduced cell-cell adhesion [24] , while calpain cleavage of E-cadherin is involved in tumor progression [53, 57] . Thus, deletion of the cytoplasmic domain of cadherins results in distinctly different cell biological effects than does deletion of the PECAM-1 cytoplasmic domain. Su et al. has shown that the decreased barrier function could be attributed to the increased degradation of VE-cadherin after the truncation [49] . Although, as important components at intercellular junctions, PECAM-1 and cadherins share some similarities in terms of structure and functions, cadherins and PECAM-1 are quite distinct in their lateral border localization and detergent extractability [3] , reflecting differences in their mode of association with the cytoskeleton. As for PECAM-1, Ayalon et al. reported > 20 years ago that a proportion of PECAM-1 is associated with the Triton-insoluble cytoskeleton in endothelial cells [3] , and there are numerous reports that PECAM-1 may be linked to the cytoskeletal adapter molecules, β and γ catenin [5] [6] [7] 22, 23] , though this has not been universally observed [29] . Wong et al. reported that PECAM-1 can be associated in cis with the integrin αvβ3 [55] , which is in turn associated with the actin cytoskeleton. In stimulated platelets, PECAM-1 may be linked to the actin cytoskeleton through the cytosolic adaptor protein, moesin [18] , and in endothelial cells under conditions of fluid shear stress with the intermediate filament protein vimentin [12] . Whether these or other cytoskeletal proteins associate with PECAM-1 to restrict its mobility under resting or shear conditions, or in response to endothelial cell injury should be a fascinating topic for future investigations.
Conclusions
These results demonstrate that, in the absence of its cytoplasmic domain, PECAM-1 is freer to diffuse within the plane of the plasma membrane, migrate to, and become concentrated at endothelial cell-cell junctions, where it engages in homophilic interactions that establish and maintain barrier function. Whether other mechanisms may account for regulation of endothelial barrier function by the truncation of PECAM-1's cytoplasmic domain remains an intriguing question, the elucidation of which will have important implications for understanding the pathological processes in vascular permeability disorders.
Materials and methods
Antibodies
Domain-specific mouse anti-human PECAM-1 monoclonal antibodies (mAbs) used in this study include: 235.1 (specific for the Cterminal 15 amino acids), and PECAM-1.3 (specific for Ig Domain 1), and have been previously described [38, 56] . Normal mouse IgG and secondary antibodies were purchased from Thermo Fisher Scientific (Waltham, MA). Alexa Fluor® 647-labeled mAb PECAM-1.3 and Alexa Fluor® 647-labeled mAb 235.1 were generated using a labeling kit purchased from Thermo Fisher Scientific (Waltham, MA).
Guide RNA plasmid constructs
Guide RNAs (gRNAs) were designed using the clustered regularly interspaced short palindromic repeats (CRISPR) Design Tool (http:// crispr.mit.edu/) to minimize off-target effects and selected to precede a 5′-NGG protospacer-adjacent motif (PAM). gRNAs used in this study were: gRNA1 forward: 5′-CACCGCAGGACTCCAAGCCACATCG-3′, reverse: 5′-AAACCGATGTGGCTT-GGAGTCCTGC-3′; gRNA10 forward: 5′-CACCGAGATGCCAGTGGAAATGTCC-3′, reverse: 5′-AAACGGACATT TCCACTGGCATCTC-3′; gRNA16 forward: 5′-CACCGTTGTCGCTAC-AGAGAACGGA-3′, reverse: 5′-AAACTCCGTTCTCTGTAGCGACAAC-3′. Oligos were annealed and cloned into the BsmBI site of the Cas9 expression plasmid lentiCRISPR v2 (#52961, Addgene, Cambridge, MA) following a previously described protocol [46] .
Cell lines and transduction
Cell culture reagents were obtained from Mediatech (Manassas, VA) unless otherwise specified. Immortalized human umbilical vein endothelial cells (iHUVEC, generated by transducing HUVECs with the recombinant retrovirus LXSN16 E6/E7) and PEC02 cells (generated by transducing iHUVECs with a lentivirus expressing a PECAM1-specific siRNA PEC02 - [45] ) were maintained in RPMI1640 medium (Mediatech), 10% FBS (Sigma, St Louis, MO), 5% human AB serum (Gemini, West Sacramento, CA), 100 U/ml penicillin, 100 μg/ml streptomycin, and 0.5 mg/ml endothelial cell growth supplement (Corning, Corning, NY) as previously described [45] .
Generation of a PECAM-1-deficient immortalized HUVEC line
Lentiviruses were generated and titrated by the Viral Vector Core Facility at the Blood Research Institute. iHUVECs cells were plated on 24-well plates one day before transduction, and transduced with gRNA1 lentiviral particles at an MOI of 5 in iHUVECs media containing 0.8 μg/ ml polybrene. After 48 h, media containing puromycin (0.5 μg/ml) was added. Transduced cells were stained with 30 μg/ml Alexa Fluor 647-labeled mAb PECAM-1.3 and sorted by flow cytometry (ARIA-IIIu Cell Sorter, BD Biosciences, San Jose, CA) for PECAM-1 negative cells. KO-PECAM-1 endothelial cells were maintained in iHUVEC medium containing puromycin.
Generation of ΔCD-PECAM-1 iHUVEC cell line
iHUVECs were plated on 24-well plates one day before transduction, and then transduced with a 1:1 mixture of gRNA10 and gRNA16 lentiviral particles at an MOI of 5 in iHUVECs media containing 0.8 μg/ml polybrene. Forty-eight-hours post-transduction, puromycin (0.5 μg/ml) was added to the medium. Cells were sorted as single cells into individual wells of 96-well plates 15 to 18 days post-puromycin selection. HUVECs in which PECAM-1 had been knocked down using an siRNA (PEC02 cells [45] ) were used as feeder cells. Three weeks later, clones were stained by 30 μg/ml Alexa Fluor 647-labeled mAb PECAM-1.3 and sorted by flow cytometry to obtain a PECAM-1-positive population, and puromycin was introduced into the medium for 48 h to further remove the feeder cells.
Characterization of endothelial cell lines by flow cytometry
Flow cytometric analysis of WT-, Δ CD-, or KO-PECAM-1 iHUVECs was performed using a BD Cytofix/Cytoperm™ (BD Biosciences, San Jose, CA) according to the manufacturer's directions. Briefly, Alexa Fluor® 647-labeled mAb PECAM-1.3 (30 μg/ml) was used in surface staining, and Alexa Fluor® 488-labeled mAb 235.1 (30 μg/ml) was used in intracellular staining. Flow cytometry was performed using a BectonDickenson LSRII (BD Biosciences, San Jose, CA). Flow cytometry data were analyzed using FlowJo software (Tree Star Inc., Ashland, OR).
Confocal microscopy
Cells were plated at a density of 2 × 10 5 /well on gelatin-coated slide chambers (BD Biosciences) at least 24 h before staining. Wells were rinsed with DPBS, cells fixed with 2% paraformaldehyde for 20 min, and then permeabilized with ice-cold 0.5% Triton X-100 for 2 min, and blocked with PBS containing 3% BSA. Monolayers were then incubated with mAb PECAM-1.1 (10 μg/ml) at room temperature for 1 h. Binding was detected using Alexa Fluor 647 anti-mouse IgG (Invitrogen) and images were obtained using a FluoView FV1000 multiphoton emission microscope (Olympus, Center Valley, PA). Cross sectional reconstruction was accomplished with MetaMorph (Molecular Devices, Inc., Nashville, TN) workstation to combine the entire Z series into a stacked projection.
ECIS measurements of endothelial barrier function
Cells were grown to confluence on gold electrodes that had been coated with 0.1% gelatin (Invitrogen, Carlsbad, CA) for an hour at 37°C and subjected to Electric Cell-substrate Impedance Sensing (ECIS) analysis using an ECIS Z-Theta Instrument (Applied Biophysics, Troy, NY). To measure PECAM-1-mediated endothelial cell barrier function, cells were grown in 400 μl of iHUVEC medium on 8W10E + electrode arrays until forming a tight monolayer. After stimulating cells with 1 unit of human thrombin (Sigma-Aldrich, St. Louis, MO), endothelial barrier disruption and restoration were measured in real time and continuously recorded at multiple frequencies and modeled with ECIS software (Applied Biophysics, Troy, NY) to obtain the barrier function parameter, Rb, which is expressed as the average basal electrical resistances (in Ω cm 2 ).
Generation and characterization of endothelial cell lines expressing GFP-PECAM-1 chimeric proteins
A silent mutation was introduced into the PAM sequence corresponding to guide 1 in PECAM-1 cDNA using QuikChange II site-directed mutagenesis (Agilent Technologies, Santa Clara, CA) in order to protect it from CRISPR/Cas9 using the following oligonucleotide primers: (1) Fwd, 5′-GGTGGGCCCAAGGGGCGACCATGTGGCTTGGAGTC-3′; (2) Rev., 5′-GACTCCAAGC-CACATGGTCGCCCCTTGGGCCCACC-3′ (silent mutation sites are underlined). Mutated full-length human PECAM-1 or ΔCD PECAM-1 was inserted into the backbone plasmid pLenti CMV GFP Neo (Addgene # 17447) using an In-Fusion® HD Cloning Kit (Clontech, Laboratories, Inc., Mountain View, CA) to generate a GFP-PECAM-1 chimeric protein. A linker sequence was inserted between GFP and the mutated WT-PECAM-1 or ΔCD-PECAM-1. The primers for GFP-WT-PE chimeric protein were: forward, 5′-GGTGGCGGAGGCTCTCAAGAAAA CTCTTTCA-CAATCAACAG-TGTT-3′; reverse, 5′-GAGGTTGATTGTC GACCTAAGTTCCATCAAGGG-AGCCTT-3′. The primers for GFP-ΔCD-PECAM-1 chimeric protein were: forward, 5′-GGTGG-CGGAGGCT CTCAAGAAAACTCTTTCACAATCAACAGTGTT-3′; reverse, 5′-GAGGTTG-ATTGTCGACCTACTTGGCCTTGGCTTTCCTCA-3′. KO-PECAM-1 cells were seeded in 24-well plates and transduced with lentiviral particles containing GFP-WT-PECAM-1 or GFP-ΔCD-PECAM-1 at an MOI of 5 in 0.8 μg/ml polybrene-containing iHUVEC media. Transduced cells were further selected by addition of 0.5 mg/ml G418 48 h post-transduction. Cell lines were sorted for Alexa Fluor 647-labeled mAb PECAM-1.3-positive expression.
Fluorescence recovery after photobleaching (FRAP)
Cells were plated on a 60 mm-diameter dish (Celltreat, Pepperell, MA) and cultured for at least 24 h until cell monolayers had reached confluence. FRAP experiments were designed and performed as previously described [14] using an FV1000 laser-scanning confocal microscope (Olympus, Tokyo, Japan) with a 100× objective lens. GFP fluorescence was imaged by excitation with a 488-nm laser at 37°C with 5% CO 2 using an Air-Therm-H heater (World Precision Instrument, Sarasota, FL). The region of interest at cell-cell contacts was selected and bleached for 300 ms using a 405 nm laser. Fluorescence intensity was monitored continuously and images were acquired until recovery reached a plateau using the FluoView-ASW-10 version 04.02.02.09 software (Olympus, Tokyo, Japan). The fluorescence intensity of the bleached region was corrected for photobleaching and normalized to prebleaching fluorescence intensity by ImageJ (NIH, Bethesda, MD). This algorithm allows computation of the diffusion coefficient of the fluorescent probes (2D random walk). Prism 5 software (GraphPad Software, San Diego, CA) was used for plotting the data and statistical analysis.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5 software (GraphPad Software, La Jolla, CA). Data were analyzed by one-way ANOVA followed by Holm-Sidak's multiple-comparisons test. Multiple comparisons tests were only applied when a significant difference was determined in the ANOVA (P < 0.05). Results are expressed as mean ± S.D.
